When it comes to migraine treatments, one-size-fits-all does not apply. Fortunately, a new option is on the horizon. Atzumi — a dihydroergotamine (DHE) nasal powder — received approval from the U.S.

When you buy through links on our articles, Future and its syndication partners may earn a commission. A GLP-1 agonist, the same class of drugs as Ozempic, may treat migraine, a study finds. | Credit: ...

Recent clinical research has unveiled groundbreaking results for Atogepant, a preventive medication offering new hope for chronic migraine sufferers. The comprehensive study published in Neurology ...

The U.S. Food and Drug Administration has approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant) - the first and only migraine treatment of its kind to be offered in nasal spray.

If you’ve ever experienced a migraine, you understand the debilitating pain that can leave you seeking refuge in a dark, quiet room for hours or even days. Now, groundbreaking research examining ...

JONESBORO, Ark. (KAIT/EDITED NEWS RELEASE) - A grant is funding research in Region 8 to help those who suffer from migraines. A faculty member at New York Institute of Technology College of ...

The American College of Physicians (ACP) issued a clinical guideline for episodic migraine prevention that varied from what migraine experts recommend. The ACP guideline, published in Annals of ...

The first migraine-specific tool to measure perceived external stigma reveals that patients worry most about misconceptions of secondary gains and minimization of their disease burden, new research ...